Clinical Trials Browser

INDUSTRY × niraparib × Genitourinary × Clear all

NCT03748641 2026-03-16

MAGNITUDE

Phase 3 Active not recruiting

765 enrolled 16 charts 1 FDA

Prostatic Neoplasms, Castration-Resistant

NCT04577833 2026-03-13

A Study of Comparative Formulations of Niraparib and Abiraterone Acetate (AA) in Men With Prostate Cancer

Phase 1 Active not recruiting

Prostatic Neoplasms

NCT04497844 2026-02-13

AMPLITUDE

Phase 3 Active not recruiting

696 enrolled 15 charts 1 FDA

Metastatic Castration-sensitive Prostate Cancer

NCT03869190 2026-01-22

Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatments and Combinations in Patients With Urothelial Carcinoma (MORPHEUS-UC)

Phase 1/2 Completed

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell

NCT03431350 2025-12-23

QUEST

Phase 2 Active not recruiting

136 enrolled 29 charts

Prostatic Neoplasms, Castration-Resistant

NCT02854436 2025-12-22

Galahad

Phase 2 Completed

289 enrolled 18 charts

Prostatic Neoplasms

NCT05169437 2025-10-29

PAVO

Phase 2 Terminated

22 enrolled 17 charts

BreastDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckThoracic

Breast Neoplasms, Colonic Neoplasms, Esophageal Neoplasms, Head and Neck Neoplasms, Lung Neoplasms, Melanoma, Neoplasm Metastasis, Pancreatic Neoplasms, Urologic Neoplasms, Endometrial Neoplasms

NCT05401214 2025-06-13

Pre-approval Access Single Patient Request for Niraparib / Abiraterone Acetate Combination (Nira/AA Combination)

Approved for marketing

Metastatic Castration-resistant Prostate Cancer

NCT02924766 2020-07-20

A Safety and Pharmacokinetics Study of Niraparib Plus an Androgen Receptor-Targeted Therapy in Men With Metastatic Castration-Resistant Prostate Cancer (BEDIVERE)

Phase 1 Completed

Prostatic Neoplasms